RE: NewcomerWell, the timing of Jaroki and George Stark couldn't be better. No sooner do they announce their departure and the stock moves up strongly, no doubt based upon the phase II clinical trial results currently being conducted at Duck University.
This is a super speculative stock and in a different environment, I belive medicure would be trading more actively and at higher levels. That being said, it is a small part of my portfolio and comes from profits made in the O&G sector, especially energy trusts that pay out 22 percent per year. This revenue funds my speculative interests but to a very limited extent. That being said, lets hope for a nice bounce to a buck or two. Certainly there are investors that have watched it fall steadily from 8 bucks three years ago.